Affordability and pricing

Partnering with UHC2030

AstraZeneca has become a private sector partner of the UHC2030 global movement to build stronger health systems for Universal Health Coverage (UHC).

This is in line with our commitment to work together to accelerate progress towards UHC, through building and expanding equitable, resilient and sustainable health systems, in line with the UHC2030 mission.

FazBem supporting patients in Brazil since 2008

We have a variety of patient access programmes in emerging markets, each tailored to meet the needs of the local community. 

Our FazBem programme has been in operation since 2008, when it first offered medicines at a discounted price in Brazil. Additional services and patient communications have been added and over three million patients have been reached.

In 2021 there were over 693,000 patient purchases and FazBem is present in more than 45,000 pharmacies.

Affordable genetic testing for ovarian cancer

We have entered into a partnership with a diagnostics company called AmoyDx to make genetic testing for ovarian cancer more affordable. Our goal is to improve access to testing which identifies homologous recombination deficiency (HRD), a biomarker for cancer. Building on our bridging programme for advanced ovarian cancer (AOC), patients in eight regional referral hubs in Asia (Singapore- Lucense and Malaysia-Pantai and India- Strand Life Sciences), Latin America (Brazil-Pardini), Russia (02 Research Centres for MG) and Middle East and Africa (Egypt-Anwaa and Greece- Genotypos) in 2021. The programme supports patients until they have HRD testing reimbursement, with the company covering the cost of testing in more than 20 countries around the world.

Addressing barriers for severe asthma patients

Our 360° Patient Support Programme addresses the main barriers and challenges facing severe asthma patients in the Gulf, and improves their patient journey by connecting them with their healthcare professionals and nurses through a digital platform.

More than 85% of the United Arab Emirates population have partial or limited access to innovative products due to lack of insurance coverage or high co-payment levels. The programme offers a variable cost sharing patient assistance programme, customised based on each patient’s ability to pay, which is assessed by a deep financial evaluation implemented by a third party to determine the treatment plan.

The treatment cost is shared by the patient and/or their insurance, non-governmental organisations and AstraZeneca, to ensure the sustainability of the programme.